New analysis adds to existing evidence that Omada’s program paired with GLP-1 medications leads to greater weight loss and persistence than reported in real world evidenceSAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced results from a 12-month real-world analysis of members in its GLP-1 companion program. By extending a previous six-month analysis, findings underscore the program’s role in helping employers m ...